GENIXUS, a pharmaceutical company focused on acute and critical care medicines, launched its KinetiX syringe platform, Rocuronium Bromide Injection. The launch is in response to the recent natural disaster impacting Pfizer’s manufacturing site in Rocky Mount, NC, and the expected impact on the sterile injectables market as a result.

KinetiX Rocuronium Bromide Injection is the second product in the syringe platform following GENIXUS’ launch of repackaged Propofol 10mL & 20mL RTA syringes earlier this year.

Key attributes inherent in the KinetiX platform:

• Intuitive labeling and color-coded plunger rod to support rapid identification
• Auto-dispensing cabinet (ADC) ready to keep product proximal to delivery site
• RFID-enabled with KitCheck, the latest technology in kit and tray management
• 5mL and 10mL RTA syringes offer flexibility to minimize waste
• Durable polymer syringe is clear and eliminates risks of glass
• 3-month beyond use date (BUD) at launch
• Stability enhancements will be shared as program data become available

“Our thoughts are with the individuals impacted by the natural disaster at Rocky Mount,” said CEO of GENIXUS, Kendall Foster. “We understand the gravity of the situation and the critical need for medications in the market. GENIXUS is committed to taking swift action to address these challenges and ensure patients have access to the medications they require.”

GENIXUS’ chief commercial officer, Seth Coombs, explained that the company’s determination to accelerate the launch of Rocuronium Bromide Injection to address the ongoing, and expected worsening, of shortages in the U.S. market. “GENIXUS is fully dedicated to doing our part to support patient care during this critical time. Our decision to fast-track the development and market entry of Rocuronium Bromide Injection reflects our commitment to supporting the availability of essential medications for patients across the country,” said Coombs.